ABSTRACT
COMMENTS
The biological disease-modifying antirheumatic drugs (DMARDs) cited in this systematic review on treatments for rheumatoid arthritis have been approved by the Food and Drug Administration (FDA) in the United States and by the Brazilian Health Surveillance Agency (ANVISA) whenever at least one non-biological DMARD (methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline) has failed or been ineffective in attempts to control the inflammatory activity. Biological DMARDs may or may not be used in association with non-biological DMARDs, except for rituximab, which is indicated after previous use of another biological DMARD has failed or been ineffective and therefore is indicated for cases of greater severity. Anakinra is not available in Brazil (used in < 5% of rheumatoid arthritis cases using biological DMARDs in the United States). All are equally effective when compared with placebo. It would be desirable if there were significant studies that made comparisons between the biological agents ("head-to-head"). Among the studies discussed in this review, the lack of uniformity among them with regard to disease severity, duration, prognostic criteria present and type and length of previous use of non-biological DMARDs were noteworthy.
Regarding the safety of these drugs, all of them, without exception, have potential adverse effects (mainly facilitating the emergence of infections). There are still no consistent conclusions regarding the potential for development of malignancy.
Currently, treatment of rheumatoid arthritis with biological agents should be indicated based on the individual characteristics of each rheumatoid arthritis patient (aggressiveness of the disease, prognostic factors, sequelae, comorbidities etc.); on the cost-effectiveness of the treatment; and, especially, on the consensus that has been reached with the patient, after extensive discussion about the possible benefits, side effects and risks from the treatment. 1, 2 
